Psyence Biomedical
8 hedge funds and large institutions have $831K invested in Psyence Biomedical in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8.43% more ownership
Funds ownership: 0% → 8.43% (+8.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$375K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$305K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$62.6K |
| 4 |
CAC
Cowen and Company
New York
|
+$29.2K |
| 5 |
VF
Virtu Financial
New York
|
+$29.2K |
Top Sellers
PBM Hedge Fund Activity: Q1 2024 in Review
8 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q1 2024, worth a combined $831K.
Buyers outnumbered sellers: 8 funds opened new PBM positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $375K.
- 8 institutional investors held Psyence Biomedical (PBM) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $831K of Psyence Biomedical stock for Q1 2024.
- 8 funds opened new Psyence Biomedical positions in Q1 2024 and 0 closed out, a net change of +8 holders.
- The largest Psyence Biomedical buyer in Q1 2024 was Cantor Fitzgerald, an estimated $375K added.
Based on aggregated 13F filings for Q1 2024.